RPRX Stock Analysis: Buy, Sell, or Hold?
RPRX - Royalty Pharma plc Class A Ordinary Shares
$46.33
-0.02 (-0.04%)
▼
5d:
+1.58%
30d:
+0.26%
90d:
+18.13%
BUY
MODERATE Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
RPRX is down 3.2% this week, but smart money is accumulating calls. Top strike: $40 2026-04-17 with 1,148 OI. Call ratio: 98% View Scanner →
Strength: 6.4/10
Get Alerted When RPRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RPRX shows positive signals but monitor for confirmation. Market pricing in 1.6% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: RPRX shows positive signals but monitor for confirmation. Market pricing in 1.6% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$58.47
Based on 5.8% avg growth
INTRINSIC VALUE TODAY
$36.31
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RPRX is currently trading at $46.33, which is considered slightly high relative to its 30-day fair value range of $45.24 to $46.66. The stock's valuation (Forward PE: 8.5) is in line with its historical norms (8.1). At these levels, the market is pricing in 1.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, RPRX is in a strong uptrend. The price is approaching resistance at $47.54. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $51.56 (+11.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RPRX is in a strong uptrend. The price is approaching resistance at $47.54. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $51.56 (+11.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$45.24 -
$46.66
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.8%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($51.56)
- NEUTRAL: Market pricing in 1.6% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$45.24 -
$46.66
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$44.73
Resistance Level
$47.54
Current Trend
Strong Uptrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.51
Wall Street Target
$51.56
(+11.2%)
Revenue Growth (YoY)
4.8%
Earnings Growth (YoY)
9.0%
Profit Margin
32.4%
Valuation Premium vs History
+1.6% premium
PE vs Historical
8.5 vs 8.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.6%
(market-implied from PE analysis)
1-Year Target
$47.09
(+2%)
2-Year Target
$47.85
(+3%)
3-Year Target
$48.61
(+5%)
3-Yr Target (if PE normalizes)
(PE: 9→8)
PE COMPRESSION
$46.28
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 7.6%)
$152.13
(+228%)
Base:
(SPY PE: 8.5, Growth: 7.6%)
$57.79
(+25%)
Bear:
(PE: 7.2, Growth: 7.6%)
$49.12
(+6%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (25x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 25.48 | Current EPS (TTM): $1.78
Bull Case
$99.79
(+119%)
Analyst growth 100.0%, PE expands to 28.0
Base Case
$90.72
(+99%)
Market implied 100.0%, PE stable at 25.5
Bear Case
$30.84
(-32%)
Severe decline -20.0%, PE contracts to 21.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: March 30, 2026 10:11 AM ET
Data refreshes hourly during market hours. Next update: 11:11 AM
Data refreshes hourly during market hours. Next update: 11:11 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RPRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Terrance P Coyne
SELL
34791 shares
2026-03-02
Terrance P Coyne
SELL
20163 shares
2026-02-04
Terrance P Coyne
SELL
114954 shares
2026-02-03
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 54 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 53 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 53 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 57 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 60 BUY |
Advanced RPRX Option Strategies
Professional options setups generated by AI based on today's RPRX price and gamma walls.
